



Mark C. Poznansky, M.D., Ph.D., F.R.C.P, F.I.D.S.A.

Director, Vaccine and Immunotherapy Center

Associate Professor of Medicine, Harvard Medical School

Steve and Deborah Gorlin MGH Research Scholar

Attending Physician, Infectious Diseases Medicine, Massachusetts General Hospital

Dr. Poznansky is a medical innovator whose work bridges academic discovery and clinical care. As a leader in the field of leukocyte migration and the modulation of leukocyte trafficking and function, he has linked discovery with the development of new vaccines and immunotherapies for infectious diseases including COVID-19, cancer and immune mediated diseases including type 1 diabetes. Dr. Poznansky has gained recognition for establishing a new model for translational research that accelerates the process by which basic biological discoveries move towards products and technologies that improve patient care and treatment. Since 2008 he has served as the founder and director of the Vaccine and Immunotherapy Center (VIC) at MGH, which is putting this model into practice. The goal of VIC is to enable efficient and rapid transition of promising technologies through preclinical development and into the clinical stage of development through technology spin outs, partnerships or out-licensing. He oversees the research work of a team of investigators, postdoctoral fellows and other trainees addressing key research questions regarding these new therapeutics and vaccines and leads an operational team that facilitates the execution of business, regulatory, manufacturing, and other developmental tasks associated with the preclinical translation of these candidates. VIC currently has 9 vaccines and immunotherapies in development, including a new self-assembling T cell targeted COVID-19 vaccine. Four of these technologies have recently reached large animal preclinical or first in human testing. The team at VIC has also developed a novel high dimensional immunology program that uses state of the art omics technologies to define broad immune profiles in cancer, infectious and immune mediated diseases to inform diagnosis, clinical decision making and vaccine and immunotherapy design. Dr. Poznansky is the scientific founder of Celtaxys, ACTx, Vicapsys, Aperisys and Voltron Therapeutics.

www.advancingcures.org

www.covid-recovery.org

